In hepatocellular carcinoma, aberrant activation of the PI3K/AKT/mTOR pathway—often due to PIK3CA mutations—is closely associated with aggressive tumor behavior and poor clinical outcomes. Here, MTOR is linked to hepatocellular carcinoma.